<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793426</url>
  </required_header>
  <id_info>
    <org_study_id>FORMA-07</org_study_id>
    <nct_id>NCT03793426</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency</brief_title>
  <official_title>Post-marketing Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, Uncontrolled, Multicenter Observational Study on the Safety and Efficacy of&#xD;
      Fibryga in Congenital Fibrinogen Deficiency&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a need to increase the body of data on treatment effectiveness and safety in the&#xD;
      ultra-rare setting of congenital fibrinogen deficiency. Real-world evidence (RWE) derived&#xD;
      from non-interventional studies can describe product utilization, demonstrate value, and&#xD;
      facilitate benefit-risk assessments; RWE can only be fully assessed once a product is&#xD;
      launched and used in a real-life setting.&#xD;
&#xD;
      This post-marketing, observational study is designed to collect information concerning&#xD;
      safety, efficacy, and outcomes of Fibryga administration in routine clinical use in patients&#xD;
      of any age with congenital afibrinogenemia or hypofibrinogenemia. Documentation of the&#xD;
      administration of Fibryga in clinical practice for the treatment of both minor and major&#xD;
      bleeding events (BEs) will not only enhance the knowledge on the efficacy and safety profile&#xD;
      of Fibryga, but will also gather information that cannot be obtained in the same way in&#xD;
      controlled clinical studies. These observational data will support the safety and efficacy&#xD;
      data generated with Fibryga in good clinical practice (GCP) clinical studies, providing&#xD;
      benefit for both physicians and patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of thromboembolic adverse drug reactions (ADRs)</measure>
    <time_frame>Day 0-28</time_frame>
    <description>The incidence of thromboembolic ADRs in patients receiving Fibryga for on-demand treatment of bleeding, including major bleeding, will be documented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemostatic efficacy of Fibryga for all bleeding events (BEs) collected in the study will be assessed by the investigator using a 4-point hemostatic efficacy scale</measure>
    <time_frame>Within 2-24 hours following treatment of BEs</time_frame>
    <description>The hemostatic efficacy of Fibryga for all BEs collected in the study will be assessed by the investigator using a 4-point hemostatic efficacy scale including the four items: 'excellent,' 'good,' moderate,' and 'none'. These data will be transformed into a dichotomous result, with 'treatment success-yes' defined as a rating of 'excellent' or 'good' and 'treatment success-no' defined as a rating of 'moderate' or 'none'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Fibryga</measure>
    <time_frame>Within 2-24 hours following treatment of BEs</time_frame>
    <description>Fibryga will be individually dosed as per the locally approved package insert. Actual dosage administered will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of BEs</measure>
    <time_frame>Within 2-24 hours following treatment of BEs</time_frame>
    <description>Details of BE duration will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety)</measure>
    <time_frame>Day 0-28</time_frame>
    <description>All ADRs in patients receiving Fibryga for on-demand treatment of BEs, including major BEs, will be documented</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Congenital Fibrinogen Deficiency</condition>
  <arm_group>
    <arm_group_label>Fibryga</arm_group_label>
    <description>Fibryga (human plasma-derived fibrinogen concentrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibryga</intervention_name>
    <description>Human plasma-derived fibrinogen concentrate</description>
    <arm_group_label>Fibryga</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 25 patients with a documented diagnosis of congenital afibrinogenemia or&#xD;
        hypofibrinogenemia are planned to be documented in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of any age with a documented diagnosis of congenital afibrinogenemia or&#xD;
             hypofibrinogenemia expected to require on-demand in-hospital treatment for BEs with&#xD;
             Fibryga&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bleeding disorder other than congenital fibrinogen deficiency&#xD;
&#xD;
          -  Patients with acquired fibrinogen deficiency or dysfibrinogenemia&#xD;
&#xD;
          -  Suspicion of an anti-fibrinogen inhibitor as indicated by previous in vivo recovery,&#xD;
             if available, of &lt;0.5 (mg/dL)/(mg/kg); there is currently no standard test for&#xD;
             inhibitors&#xD;
&#xD;
          -  Participation in an interventional clinical study at the time of or within 4 weeks&#xD;
             prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Schwartz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Octapharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Schwartz, PhD</last_name>
    <phone>+12016041112</phone>
    <email>bruce.schwartz@octapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvia Werner, MS</last_name>
    <phone>+12016041149</phone>
    <email>sylvia.werner@octapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Klinik 2 / Institut für Transfusionsmedizin Universitätsklinikum</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gerinnungszentrum Hochtaunus</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa S Alesci</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

